Knowledge base
Articles and guides
KRS data analyses, industry rankings and guides on companies, share capital and financial statements - backed by real examples.
Explainer
JSW in 2026: Europe's largest coking-coal producer, an mWIG40 issuer from Jastrzębie-Zdrój, six mines under State-Treasury control
Jastrzębska Spółka Węglowa S.A. (KRS 0000072093), headquartered at Aleja Jana Pawła II 4 in Jastrzębie-Zdrój, is Europe's largest producer of coking coal (used in steelmaking, unlike Bogdanka's thermal coal). Controlled by the State Treasury and listed on the WSE since July 2011, the mWIG40 constituent operates six mines in the Upper Silesian Coal Basin. Its 2025 financial statements show PLN 9.4bn in revenue and a PLN 6.2bn net loss – the trough of the coke-price cycle.
May 2, 2026 · updated July 27, 2026
News
Kogeneracja 2026: EBITDA of PLN 579m (+29% YoY), net profit of PLN 277m (+37%) - first full year of the EC Czechnica-2 gas unit (315 MWt + 179 MWe)
Wrocław-based Zespół Elektrociepłowni Wrocławskich KOGENERACJA S.A. (KRS 0000001010), part of the PGE Energia Ciepła group controlled by PGE Polska Grupa Energetyczna, closed 2025 with EBITDA of PLN 579m (+PLN 131m, +29.2% YoY) and net profit of PLN 277m (+PLN 75m, +37%). Revenue per the 2025 financial statements reached PLN 2.65bn (+3.7% YoY). Electricity sales hit 2,837 GWh (+31% YoY), driven mainly by the EC Czechnica-2 gas-steam unit commissioned in May 2025 (315 MWt + 179 MWe). Heat sales rose 6% YoY on a colder 2025. CO2 allowance costs fell by PLN 112m, while capacity-market and high-efficiency cogeneration support revenue rose by PLN 57m.
May 2, 2026 · updated July 27, 2026
Explainer
Text (formerly LiveChat) in 2026: a Wrocław SaaS under a new brand after the 2024 rebrand, a two-member management board, an mWIG40 issuer exporting to the US
Text S.A. (KRS 0000290756), headquartered at ul. Zwycięska 47 in Wrocław, is the Wrocław SaaS company previously known as LiveChat Software, offering customer-support products (LiveChat chat widget, HelpDesk, ChatBot, KnowledgeBase). In 2024 the company rebranded from LiveChat Software to Text S.A. Founded in 2002 by Mariusz Ciepły, listed on the WSE since 2014, the company is an mWIG40 constituent. A two-member management board (one of the smallest in the mWIG40), a five-member supervisory board.
May 2, 2026 · updated July 27, 2026
News
Longevity Center launches Longevity Academy: Poland's first accredited longevity-medicine educational programme for doctors
Warsaw-based Longevity Center sp. z o.o. (KRS 0000796083, ul. Belwederska 9) has launched Longevity Academy - one of the world's first and Poland's first accredited longevity-medicine educational programme for doctors. Accreditation comes from the Polish Medical Chamber; the scientific partner is the Buck Institute for Research on Aging in California. The programme is built on 6+ years of clinical practice and 3,000+ patients.
May 2, 2026 · updated July 27, 2026
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
May 2, 2026 · updated July 27, 2026
News
MCI Capital 2026: record PLN 815m exits – IAI Group sold for over PLN 1bn, NAV of PLN 2.1bn, PLN 83m dividend recommendation
Warsaw-based MCI Capital ASI S.A. (KRS 0000004542) closed 2025 with net profit of PLN 45.5m and NAV of PLN 2.1bn. The year's key transaction was the sale of IAI Group to Montagu PE for over PLN 1bn (PLN 470.5m of net proceeds to MCI.EuroVentures 1.0) – the largest CEE B2B-software deal of 2025. Total 2025 exits reached around PLN 815m (from transactions worth over PLN 890m), including Answear, Gett, Netrisk, and Webcon. Under its 4%-of-equity dividend policy, the board recommends PLN 83m (a yield of around 5.6%). Portfolio companies generate over PLN 500m of normalised EBITDA; the 26-year NAV CAGR is around 15%.
May 2, 2026 · updated July 27, 2026
News
Medicalgorithmics 2026: first positive quarterly EBITDA (Q4 2025: +PLN 1m), revenue of PLN 31m (+29% YoY), US up 452% YoY
Warsaw-based Medicalgorithmics S.A. (KRS 0000372848), maker of the flagship PocketECG remote heart-rhythm monitoring system, closed 2025 with revenue of PLN 31m (+29% YoY) and reached its first positive quarterly EBITDA in Q4 2025 (+PLN 1.0m), with the net loss narrowing to PLN 11.7m. Q4 alone: revenue of PLN 10.2m (+74% YoY, +42% QoQ), including PLN 4.8m from the US market (+452% YoY), and around 135,000 ECG studies (+70% YoY). 2025 milestones: FDA approval for the DRAI algorithms, a USD 5.9m Canadian contract for over 2,000 Kardiobeat.ai devices, partnerships with Wellysis (Samsung) and CardioScan (Australia), and the first VCAST contracts (Sweden, Turkey).
May 2, 2026 · updated July 27, 2026
News
Medinice 2026: FDA for CoolCryo, CE MDR for PacePress, PLN 8.7m for AtriClamp – cardiology medtech at a regulatory breakthrough
Warsaw-based Medinice S.A. (KRS 0000443282), a pre-commercial medtech developing five innovative cardiac-surgery devices (PacePress, CoolCryo, AtriClamp, MiniMax, EP Bioptom), secured FDA certification for CoolCryo and CE MDR for PacePress in 2025, plus PLN 8.7m of EU funding for AtriClamp. Q1 2025: parent revenue of PLN 56k, a net loss of PLN 1.0m (versus PLN 1.2m), equity of PLN 38.4m. PacePress: a clinical trial closed early with a positive result, commercialisation targeted for 2025. CoolCryo: a 510K filed in Q2 2025, with 14 patients in the European trial.
May 2, 2026 · updated July 27, 2026
News
Mennica Polska 2026: Q1 revenue up 80% YoY (PLN 726.7m), 838 kg of investment gold, Bulwary Praskie 95% sold, PLN 1.50 dividend
Warsaw-based Mennica Polska S.A. (KRS 0000019196), the only Polish producer of investment-gold bars, with three independent business legs (minting, the City Card transit-ticketing business, and the Bulwary Praskie development), posted Q1 2026 revenue of PLN 726.7m (+80% YoY versus PLN 402.9m) and EBITDA of PLN 56.4m (+28%). Investment-gold sales: 838 kg (+38% by weight YoY). 2025 closed with revenue of around PLN 1.83bn (+31%), EBITDA of around PLN 160m (+29%), and net profit of around PLN 500m (a significant part from the development segment). Bulwary Praskie: 747 apartments with occupancy permits, 95% sold or reserved. Recommended dividend: PLN 1.50 per share (PLN 76.5m).
May 2, 2026 · updated July 27, 2026
Explainer
Mercator Medical in 2026: a Kraków-based medical-glove producer with plants in Thailand, an mWIG40 issuer after the COVID meme-stock cycle
Mercator Medical S.A. (KRS 0000036244), headquartered at ul. Modrzejewskiej 30 in Kraków, is a Polish producer and distributor of single-use medical gloves (nitrile and latex) and other disposables. The company controls the full value chain: plants in Thailand (Mercator Medical Thailand) plus Polish and international distribution. In 2020 the share price exploded on pandemic demand (from PLN 10 to over PLN 800), followed by a gradual normalisation. Listed on the WSE since 2013, with a three-member management board and a five-member supervisory board.
May 2, 2026 · updated July 27, 2026
News
MLP Group 2026: net profit of PLN 459m (+23% YoY), a record 370,941 sqm leased and the first dividend policy since 2019
Pruszków-based MLP Group S.A. (KRS 0000053299), a developer and operator of logistics-warehouse parks in Poland, Germany, Austria, Romania and the Netherlands, closed 2025 with net profit of PLN 459.0m (+23.3% YoY vs PLN 372.2m) and EBIT of PLN 701.7m (+29.2%). Rental revenue reached PLN 238.4m (+10%) and property-management services PLN 182.1m (+15.5%). 2025 leasing volume: a record 370,941 sqm (new leases and renewals). EPS PLN 19.13 (+23.3%), equity PLN 3,197m (+16.4%), assets PLN 6.99bn. After a seven-year break, the company has announced a dividend policy for 2026. 2026 targets: +20–30% revenue growth, around 250,000–300,000 sqm of new buildings, 60% of capex allocated to Germany.
May 2, 2026 · updated July 27, 2026
News
Mostostal Zabrze 2026: revenue of PLN 1.22bn (+21% YoY), a PLN 1.08bn backlog, net profit -45% YoY – share-buyback motion out of 2025 profit
Gliwice-based Mostostal Zabrze S.A. (KRS 0000049844), a contractor of industrial installations, steel structures for metallurgy, waste incinerators and data centres, closed 2025 with revenue of PLN 1.22bn (+21% YoY vs PLN 1.01bn) and net profit of PLN 34.3m (vs PLN 61.8m, -45%). EBIT reached PLN 45.5m (vs PLN 79.8m, -43%). The operating margin fell on the back of the Polwax integration and cost pressure. Backlog at end-February 2026: PLN 1,079.8m plus PLN 353.6m of offers – PLN 1,433m in total. On 15 April 2026 the management board filed a motion with the AGM to distribute net profit and allocate part of it to a share buyback. Net debt: PLN -176.8m (a cash surplus).
May 2, 2026 · updated July 27, 2026
